 hemorrhag event therapi recombin tissue-typ plasminogen activ heparin aspirin acut myocardi infarct result thrombolysi myocardi infarct timi phase II trial object effect invas procedur hemostat clinic variabl time beta-block therapi dose recombin plasminogen activ rt-pa hemorrhag event design multicent trial set hospit thrombolysi myocardi infarct phase II trial timi II intervent patient rt-pa heparin total dose rt-pa mg first patient mg patient patient invas strategi coronari arteriographi percutan angioplasti feasibl hour start thrombolyt therapi conserv strategi coronari arteriographi recurr spontan exercise-induc ischemia elig patient immedi intraven defer beta-block therapi measur patient hemorrhag event hospit main result patient rt-pa regimen major minor hemorrhag event common invas conserv strategi major minor hemorrhag event extent fibrinogen breakdown peak rt-pa level thrombocytopenia prolong partial thromboplastin time aptt second weight kg femal gender physic sign cardiac decompens immedi intraven beta-block therapi import effect hemorrhag event delay beta-block therapi intracrani hemorrhag frequent patient rt-pa dose rt-pa dose extent plasmin-medi hemostat defect patient dose conclus morbid due hemorrhag complic invas manag strategi patient acut myocardi infarct find complex interact sever factor occurr hemorrhag event thrombolyt therapi